SZ 780 Pill - white round, 7mm
Pill with imprint SZ 780 is White, Round and has been identified as Methylphenidate Hydrochloride SR 20 mg. It is supplied by Sandoz Pharmaceuticals Inc.
Methylphenidate is used in the treatment of ADHD; Narcolepsy; Depression and belongs to the drug class CNS stimulants. Risk cannot be ruled out during pregnancy. Methylphenidate 20 mg is classified as a Schedule 2 controlled substance under the Controlled Substance Act (CSA).
Images for SZ 780
Methylphenidate Hydrochloride SR
- Imprint
- SZ 780
- Strength
- 20 mg
- Color
- White
- Size
- 7.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- CNS stimulants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- 2 - High potential for abuse
- Labeler / Supplier
- Sandoz Pharmaceuticals Inc.
- National Drug Code (NDC)
- 00781-5754 (Discontinued)
- Inactive Ingredients
-
cetostearyl alcohol,
magnesium stearate,
zein,
methyl alcohol,
mineral oil,
titanium dioxide
Note: Inactive ingredients may vary.
Submitted by: Liverosa
More about methylphenidate
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,065)
- Drug images
- Latest FDA alerts (4)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: CNS stimulants
- Breastfeeding
Patient resources
- Methylphenidate drug information
- Methylphenidate transdermal
- Methylphenidate (Oral) (Advanced Reading)
- Methylphenidate (Transdermal) (Advanced Reading)
- Methylphenidate Chewable Tablets
Other brands
Ritalin, Concerta, Jornay PM, Ritalin LA, ... +11 more
Professional resources
- Methylphenidate monograph
- Methylphenidate CD Capsules (FDA)
- Methylphenidate Chewable Tablets (FDA)
- Methylphenidate ER Capsules (FDA)
- Methylphenidate Hydrochloride (FDA)
Other brands
Ritalin, Concerta, Jornay PM, Ritalin LA, ... +10 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
